SCHEMBL18547680

SCHEMBL18547680

O=C(O)c1ccc(C(c2ccc(Cl)cc2)c2ccc3nn(C4CC4)c(C4CCN(S(=O)(=O)C(F)(F)F)CC4)c3c2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ CNR1 P21554 20/20 1.00
▸ CNR2 P34972 8/20 0.80

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18547770 0.93 CNR1 (1.00) CNR1CNR2
SCHEMBL18547726 0.93 CNR1 (1.00) CNR1CNR2
Trifluoroacetic Acid SCHEMBL18547870 0.91 CNR1 (0.94) CNR1CNR2
SCHEMBL18547679 0.89 CNR1 (1.00) CNR1CNR2
SCHEMBL18547977 0.87 CNR1 (0.77) CNR1CNR2
SCHEMBL18554590 0.86 CNR1 (0.75) CNR1CNR2
SCHEMBL18548067 0.85 CNR1 (0.74) CNR1CNR2
SCHEMBL18547916 0.84 CNR1 (1.00) CNR1CNR2
SCHEMBL18547720 0.83 CNR1 (1.00) CNR1CNR2
SCHEMBL18547667 0.82 CNR1 (1.00) CNR1CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9682940-B2 Indazole derivatives useful as CB-1 inverse agonists JANSSEN PHARMACEUTICA NV (BE) 2017-06-20 — — US disclosed
US-20170057925-A1 INDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS JANSSEN PHARMACEUTICA NV (BE) 2017-03-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170057925-A1 INDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS CNR1, GPR119, CNR2 CNR1 1/4885CNR2 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback